NYSEMKT: APUS
Apimeds Pharmaceuticals Us Inc Earnings Dates, Reports, Calls

Apimeds Pharmaceuticals Us earnings were N/A for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest APUS earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$402.4k, up 29.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, APUS reported annual earnings of -$1.4M, with 78.7% growth.

APUS earnings history

Current Revenue
$0.0
Current Earnings
$0.0
Current Profit Margin
0%

APUS Return on Equity

Insufficient data to display

APUS undefined

Insufficient data to display

Be the first to know when APUS announces earnings.

APUS undefined

Current Company
0%
Current Industry
14.3%

APUS vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
APUSN/AN/AN/AN/A
DRRX-$5.34M-$4.91MN/A-$0.15
GELS-$1.91M-$2.30MN/A-$0.29
SCYX-$26.67M-$27.09MN/A-$0.56
RMTI$4.97M-$264.00kN/A-$0.02

Apimeds Pharmaceuticals Us Earnings Reports & History FAQ

What were Apimeds Pharmaceuticals Us's earnings last quarter?

Apimeds Pharmaceuticals Us (NYSEMKT: APUS) reported Q1 2025 earnings per share (EPS) of -$0.05, up 25% year over year. Total APUS earnings for the quarter were -$402.40 thousand. In the same quarter last year, Apimeds Pharmaceuticals Us's earnings per share (EPS) was -$0.04.

If you're new to stock investing, here's how to buy Apimeds Pharmaceuticals Us stock.

Is Apimeds Pharmaceuticals Us profitable or losing money?

As of the last Apimeds Pharmaceuticals Us earnings report, Apimeds Pharmaceuticals Us is currently losing money. Apimeds Pharmaceuticals Us's net profit (also called net income) for the twelve months ending Mar 31, 2025 was N/A, a N/A decrease year over year.

What was APUS's earnings growth in the past year?

As of Apimeds Pharmaceuticals Us's earnings date in Q2 2025, Apimeds Pharmaceuticals Us's earnings has grown year over year. APUS earnings in the past year totalled N/A.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.